Galectin Therapeutics Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 8.52 million compared to USD 5.94 million a year ago. Basic loss per share from continuing operations was USD 0.14 compared to USD 0.1 a year ago.
For the nine months, net loss was USD 23.31 million compared to USD 15.61 million a year ago. Basic loss per share from continuing operations was USD 0.4 compared to USD 0.28 a year ago.